SynthesisScientific reports2016
LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies.
Synthesis in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Statin Use and Survival Among Men Receiving Androgen-Ablative Therapies for Advanced Prostate Cancer: A Systematic Review and Meta-analysis.JAMA network open · 2022Pooled it
- Outcomes of Screening for Prostate Cancer Among Men Who Use Statins.JAMA oncology · 2022Trial
- Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study.Prostate cancer and prostatic diseases · 2018Trial
- The association between statin use, genetic variation, and prostate cancer risk.Prostate cancer and prostatic diseases · 2025Article
- Association between low density lipoprotein cholesterol levels and prostate cancer risk in non-hypertensive middle-aged and older American men.Scientific reports · 2024Article
- Effect of statins and testosterone replacement therapy on incident cardiovascular disease among male hormone-related cancer survivors.Research square · 2023Article
- Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.PLoS medicine · 2023Article
- Joint association of statins and testosterone replacement therapy with cardiovascular disease among older men with prostate cancer: SEER-Medicare 2007-2015.Cancer epidemiology · 2022Article
- The Association of Prediagnostic Statin Use with Aggressive Prostate Cancer from the Multiethnic Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- The relationship between lipoprotein A and other lipids with prostate cancer risk: A multivariable Mendelian randomisation study.PLoS medicine · 2022Article
- The tangled web of dyslipidemia and cancer: Is there any association?Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2022Review
- Crosstalk between Statins and Cancer Prevention and Therapy: An Update.Pharmaceuticals (Basel, Switzerland) · 2021Review
- The role of testosterone replacement therapy and statin use, and their combination, in prostate cancer.Cancer causes & control : CCC · 2021Article
- Independent and Joint Effects of Testosterone Replacement Therapy and Statins use on the Risk of Prostate Cancer Among White, Black, and Hispanic Men.Cancer prevention research (Philadelphia, Pa.) · 2021Article
- Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs.Current oncology reports · 2021Review
- Pharmacoepidemiological Evaluation in Prostate Cancer-Common Pitfalls and How to Avoid Them.Cancers · 2021Review
- Immunotherapeutic Strategies in Cancer and Atherosclerosis-Two Sides of the Same Coin.Frontiers in cardiovascular medicine · 2021Review
- Obesity, Type 2 Diabetes, and Cancer Risk.Frontiers in oncology · 2020Review
- Article
- Statin use and time to progression in men on active surveillance for prostate cancer.Prostate cancer and prostatic diseases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of statins in preventing prostate cancer is currently a controversial issue. The aim of this review is to investigate the effects of statins use on prostate cancer risk. Electronic databases (the Cochrane Library, PubMed, Medline, Embase, Web of Science, and ClinicalTrials.gov) were searched systematically up to April, 2015. Weighted averages were reported as relative risk (RR) with 95% confidence intervals (CIs). Statistic heterogeneity scores were assessed with the standard Cochran's Q test and I(2) statistic. The pooled estimates of randomized controlled trials (RCTs) and retrospective studies suggest that statins have a neutral effect on total prostate cancer (RR = 1·02, 95% CI: 0·90-1·14; and RR = 0·91, 95% CI: 0·79-1·02, respectively). This research provides no evidence to suggest that the use of statins for cholesterol lowering is beneficial for the prevention of low-grade or localized prostate cancer, although a plausible association between statins use and the reduction risk of advanced (RR = 0·87, 95% CI: 0·82-0·91) or high-grade prostate cancer (RR = 0·83, 95% CI: 0·66-0·99) is observed. Furthermore, it shows that prostate cancer risk does not statistically significant benefit from long-term statins use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.